Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
Anticancer Res. 2019 Aug;39(8):4357-4361. doi: 10.21873/anticanres.13604.
This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy.
Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan-Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated.
Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively.
Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible.
本研究分析了单纯接受靶向治疗的转移性肾细胞癌（mRCC）患者接受转移灶切除术对总死亡率（OM）和围手术期结局的影响。
使用监测、流行病学和最终结果（SEER）数据库（2006-2015 年），通过 Kaplan-Meier 分析和多变量 Cox 回归模型检验 OM。使用国家住院患者样本（NIS）数据库（2006-2015 年）评估并发症发生率和住院死亡率。
在 SEER 数据库中，3654 例患者中有 437 例（12.2%）接受了转移灶切除术。转移灶切除术与较低的 OM 风险相关（中位生存时间 11 个月与 9 个月，风险比=0.83；p=0.002）。在 NIS 数据库中，确定了 351 例此类患者。并发症和住院死亡率分别为 55.0%和 4.6%。
在单纯接受靶向治疗的 mRCC 患者中进行转移灶切除术与较低的 OM 风险相关，但考虑到预期生存时间较短。并发症和住院死亡率不容忽视。
